Study of sodium chloride solution injections (Localized Tissue Hydration) for adults with chronic low back pain

2 1 1 1

What is this study about?

This clinical trial focuses on evaluating a treatment for chronic low back pain, a condition characterized by back pain lasting more than 3 months that does not require surgery. The study investigates a treatment method called Localized Tissue Hydration, which involves injecting sodium chloride solution (a sterile salt water solution) under the skin in the affected area.

The purpose of the study is to determine if this tissue hydration treatment, when combined with standard care, can help reduce back pain. The treatment uses special infusion kits to deliver the salt water solution through small needles placed under the skin, creating what is called a hydration cushion in the tissue to help treat the pain locally.

During the study, participants will receive the treatment and be monitored for 6 months to assess changes in their pain levels. Pain will be measured using a simple numerical scale where patients rate their pain from 0 to 10. The total treatment period lasts 10 weeks, with follow-up visits scheduled at 3 and 6 months after treatment begins to evaluate the long-term effects of the procedure.

1 Initial evaluation

A medical assessment will be performed to confirm your eligibility for the study of chronic low back pain treatment

Your current pain level will be measured using a Verbal Numerical Scale (a pain scale from 0 to 10)

Your existing lumbar MRI results will be reviewed

2 Treatment initiation

You will receive Localized Tissue Hydration (LTH) treatment, which involves subcutaneous injections of saline solution

The treatment will be combined with standard care for low back pain

The injectable solution used will be sodium chloride 0.9% administered through subcutaneous injection

3 3-month follow-up

A follow-up visit will take place 3 months after starting treatment

Your pain level will be measured again using the pain scale from 0 to 10

The effectiveness of the treatment will be assessed

4 6-month follow-up

A final evaluation will occur 6 months after starting treatment

Your pain level will be measured for the final time using the pain scale

The success of the treatment will be determined by checking if your pain has decreased by at least 30% compared to the start of the study

Who Can Join the Study?

  • You must be 18 years of age or older
  • You must have chronic low back pain that has lasted for more than 3 months with a pain level of 5 or higher on the pain scale (where 0 means no pain and 10 means worst possible pain)
  • Your back pain condition must not require surgery
  • You must have had a lumbar MRI (a detailed image of your lower back using magnetic resonance imaging) before joining the study
  • You must be enrolled in a National Health Insurance program
  • You must be willing and able to provide written informed consent (agreement to participate in the study after understanding all the details)
  • Both men and women may participate in this study

Who Cannot Join the Study?

  • Age below 18 or above 65 years
  • Patients with acute back pain (pain lasting less than 6 weeks)
  • History of spinal surgery in the past 6 months
  • Presence of nerve root compression (when a nerve in the spine is squeezed or irritated)
  • Current malignant condition (cancer) or history of cancer in the past 5 years
  • Pregnant or breastfeeding women
  • Patients with inflammatory back conditions (such as rheumatoid arthritis or ankylosing spondylitis)
  • Severe mental health conditions that could affect participation
  • Current participation in another clinical trial
  • Known allergy to any components of the study treatment
  • Inability to follow study procedures or attend follow-up visits
  • Severe osteoporosis (significant bone weakness)
  • Uncontrolled diabetes or high blood pressure
  • Serious heart, kidney, or liver conditions

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name City Country Status
Hopital Prive Clairval Marseille France

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
France France
Not recruiting
15.03.2024

Trial locations

Investigated drugs:

Localized Tissue Hydration (LTH) is a therapeutic treatment that involves the injection of sterile water into specific tissue areas of the lower back. This treatment is designed to help manage chronic low back pain by hydrating the affected tissues. It is used alongside standard treatment methods for back pain. The procedure aims to reduce pain intensity and improve patient comfort by targeting specific areas of discomfort in the lower back region.

Standard back pain management techniques are also used in conjunction with LTH therapy. These may include conventional pain management approaches that are typically prescribed for chronic low back pain, though specific details are not provided in the source data.

Investigated diseases:

Chronic Common Low Back Pain – A persistent condition characterized by pain in the lower region of the back that lasts for more than 12 weeks. The pain typically occurs between the bottom of the rib cage and the buttock creases, often developing gradually over time. It can vary in intensity from mild to severe, and may be accompanied by stiffness in the lower back area. The condition can affect daily activities and movement patterns, potentially leading to reduced physical activity. The pain may worsen with prolonged sitting, heavy lifting, or certain movements.

Trial ID:
2024-510625-25-00
Trial Phase:
Therapeutic exploratory (Phase II)

Other Trials to Consider

  • Study comparing diclofenac, orphenadrine and paracetamol combination versus diclofenac alone and orphenadrine-paracetamol combination in patients with acute low back pain

    Recruiting

    3 1 1
    Investigated drugs:
    Greece
  • Study on Melatonin for Patients with Chronic Low Back Pain: A Randomized Trial

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands